All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
1.08 [0.79 ; 1.47 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 397 NA not evaluable deathsdetailed results Cao, 2020 0.71 [0.36; 1.40]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
0.83 [0.65 ; 1.06 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 4 42% 1,647 moderate not evaluable deaths (time to event analysis only)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
0.84 [0.62 ; 1.13 ] COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 3 59% 1,448 moderate not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
0.87 [0.55 ; 1.37 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 3 74% 803 moderate not evaluable clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
0.90 [0.62 ; 1.31 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 4 69% 1,647 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 1.59 [0.84; 3.03]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
1.01 [0.45 ; 2.26 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 78% 596 moderate not evaluable clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
1.32 [0.45 ; 3.84 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 50% 596 moderate not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.31 [0.94; 1.83]
1.31 [0.94 ; 1.83 ] Cao, 2020 1 0% NA not evaluable hospital dischargedetailed results REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
0.76 [0.59 ; 0.98 ] REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 2 40% 1,051 moderate not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
0.99 [0.61 ; 1.63 ] Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 4 48% 1,639 moderate not evaluable long QTdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
0.90 [0.56 ; 1.43 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable renal impairmentdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.44 [0.99 ; 2.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable 0.5 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-07 00:36 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
